Risk for PML in Multiple Sclerosis Predicted With Anti-JCV Antibody Index
While an efficacious treatment for relapsing MS, natalizumab is associated with risk of developing progressive multifocal leukoencephalopathy.
Having a higher burden of comorbidities is associated with greater disability progression and lower QoL, as well as increased healthcare utilization and mortality.
Investigators sought to determine relapse rates of multiple sclerosis decrease prior to pregnancy, during pregnancy, and postpartum.
Investigators propose that myelocortical multiple sclerosis may be a subtype of multiple sclerosis.